Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | HTI-1066 |
Synonyms | |
Therapy Description |
HTI-1066 is a monoclonal antibody against MET in conjugation with a cytotoxic agent, which may specifically target Met-positive tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HTI-1066 | HTI1066|HTI 1066 | MET Antibody 29 | HTI-1066 is a monoclonal antibody against MET in conjugation with a cytotoxic agent, which may specifically target Met-positive tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03398720 | Phase I | HTI-1066 | Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |